89 related articles for article (PubMed ID: 7635409)
1. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
Suou T; Hosho K; Kishimoto Y; Horie Y; Kawasaki H
Hepatology; 1995 Aug; 22(2):426-31. PubMed ID: 7635409
[TBL] [Abstract][Full Text] [Related]
2. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-alpha.
Teran JC; Mullen KD; Hoofnagle JH; McCullough AJ
Hepatology; 1994 Apr; 19(4):849-56. PubMed ID: 8138256
[TBL] [Abstract][Full Text] [Related]
3. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
4. Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
Casaril M; Capra F; Gabrielli GB; Tognella P; Rizzi A; Squarzoni S; De Maria E; Colombari R; De Sandre G; Corrocher R
Ital J Gastroenterol; 1996 Jan; 28(1):15-9. PubMed ID: 8743068
[TBL] [Abstract][Full Text] [Related]
5. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
Mitsuda A; Suou T; Ikuta Y; Kawasaki H
J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
[TBL] [Abstract][Full Text] [Related]
7. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
[TBL] [Abstract][Full Text] [Related]
8. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagasawa M; Toyama T; Ozaki S; Naito M; Azuma M
Hepatology; 1996 Jul; 24(1):27-31. PubMed ID: 8707274
[TBL] [Abstract][Full Text] [Related]
9. Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomized controlled study.
Castilla A; Camps-Bansell J; Civeira MP; Prieto J
Am J Gastroenterol; 1993 Feb; 88(2):233-9. PubMed ID: 8424427
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.
Zöhrens G; Armbrust T; Meyer Zum Büschenfelde KH; Ramadori G
Dig Dis Sci; 1994 Sep; 39(9):2007-13. PubMed ID: 8082511
[TBL] [Abstract][Full Text] [Related]
11. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
[TBL] [Abstract][Full Text] [Related]
12. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy.
Giustina G; Fattovich G; De Paoli M; Guido M; Favarato S; Rugge M; Alberti A; Ruol A; Plebani M
Int J Clin Lab Res; 1996; 26(1):33-6. PubMed ID: 8739853
[TBL] [Abstract][Full Text] [Related]
13. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
Lin DY; Chu CM; Sheen IS; Liaw YF
Dig Dis Sci; 1995 Jan; 40(1):21-7. PubMed ID: 7821112
[TBL] [Abstract][Full Text] [Related]
14. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.
Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Katano Y; Hayakawa T
J Gastroenterol Hepatol; 1996 Jul; 11(7):646-51. PubMed ID: 8840240
[TBL] [Abstract][Full Text] [Related]
15. Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy.
Shimizu I; Omoya T; Takaoka T; Wada S; Wada H; Taoka M; Hayashi H; Hayashi S; Honda H; Sano N; Ito S
J Gastroenterol Hepatol; 2001 Feb; 16(2):196-201. PubMed ID: 11207901
[TBL] [Abstract][Full Text] [Related]
16. [Significance of type III serum N-terminal peptide procollagen assay in chronic viral hepatitis C].
Pateron D; Hartmann DJ; Berrebi W; Trinchet JC; Jouanolle H; Callard P; Beaugrand M
Gastroenterol Clin Biol; 1994; 18(3):257-61. PubMed ID: 7926442
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features.
Serejo F; Emerit I; Filipe PM; Fernandes AC; Costa MA; Freitas JP; de Moura MC
Can J Gastroenterol; 2003 Nov; 17(11):644-50. PubMed ID: 14631465
[TBL] [Abstract][Full Text] [Related]
18. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
[TBL] [Abstract][Full Text] [Related]
19. Changes of serum 7S fragment of type IV collagen and N-terminal propeptide of type III procollagen after transcatheter arterial embolization as a model of acute liver injury.
Suou T; Yamada S; Kobayashi J; Hoshino U; Nishimuki E; Kawasaki H
Hepatology; 1993 Oct; 18(4):809-15. PubMed ID: 7691706
[TBL] [Abstract][Full Text] [Related]
20. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia.
Camps J; Castilla A; Ruiz J; Civeira MP; Prieto J
J Hepatol; 1993 Mar; 17(3):390-6. PubMed ID: 8391042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]